Soha Atallah1,2, Lisa Barbera1,3, Matthew Folwell1,4, Doris Howell2,5, ZhihuiAmy Liu2,6, Jennifer Croke7,8. 1. Department of Radiation Oncology, University of Toronto, 610 University Ave, Toronto, ON, M5G 2M9, Canada. 2. Princess Margaret Cancer Centre, University Health Network, 610 University Ave, Toronto, ON, M5G 2M9, Canada. 3. Department of Radiation Oncology, University of Calgary, Calgary, Canada. 4. Royal Victoria Regional Health Center, Barrie, Canada. 5. Department of Psychosocial Oncology, University of Toronto, Toronto, Canada. 6. Dalla Lana School of Public Health, University of Toronto, Toronto, Canada. 7. Department of Radiation Oncology, University of Toronto, 610 University Ave, Toronto, ON, M5G 2M9, Canada. Jennifer.croke@rmp.uhn.ca. 8. Princess Margaret Cancer Centre, University Health Network, 610 University Ave, Toronto, ON, M5G 2M9, Canada. Jennifer.croke@rmp.uhn.ca.
Abstract
OBJECTIVE: To evaluate the implementation of a cervix cancer-specific patient-reported outcome measure, the European Organization for Research and Treatment of Cancer Quality of Life Cervical Cancer module (EORTC QLQ-CX24), into gynecologic oncology clinics. METHODS: This was a prospective, multi-institutional, cross-sectional study involving cervix cancer patients previously treated with curative intent radiotherapy who were attending routine follow-up appointments. Between January 2017 and August 2018, eligible patients were approached to complete the EORTC QLQ-CX24 prior to their clinical encounter and then review it with their oncologist. Patient and oncologist experience was evaluated using Feedback Questionnaires following the encounter. Descriptive statistics were used to summarize the results of the EORTC QLQ-CX24 and Feedback Questionnaires. Open-ended questions within the Feedback Questionnaires were analyzed to identify themes. RESULTS: Eighty-four patients consented to participate in the study. Of these, 80 (95.2%) completed the EORTC QLQ-CX24 and 76 (90.4%) completed both the EORTC QLQ-CX24 and the Feedback Questionnaires. There were high rates of completion for most items within the EORTC QLQ-CX24 (93-98%), except for items pertaining to vaginal symptoms and sexual health (34-35%). All eligible oncologists participated (n = 9). Overall, patients and oncologists positively endorsed use of the questionnaire during clinical encounters. The majority of patients (80%) and oncologists (89%) reported use of the questionnaire improved communication, including discussion of sensitive topics. Interestingly, only a minority of patients and oncologists stated a perceived preference for electronic completion (18% and 44%, respectively). CONCLUSION: Implementation of the EORTC QLQ-CX24 in gynecologic oncology clinics was feasible and acceptable according to patients and oncologists.
OBJECTIVE: To evaluate the implementation of a cervix cancer-specific patient-reported outcome measure, the European Organization for Research and Treatment of Cancer Quality of Life Cervical Cancer module (EORTC QLQ-CX24), into gynecologic oncology clinics. METHODS: This was a prospective, multi-institutional, cross-sectional study involving cervix cancerpatients previously treated with curative intent radiotherapy who were attending routine follow-up appointments. Between January 2017 and August 2018, eligible patients were approached to complete the EORTC QLQ-CX24 prior to their clinical encounter and then review it with their oncologist. Patient and oncologist experience was evaluated using Feedback Questionnaires following the encounter. Descriptive statistics were used to summarize the results of the EORTC QLQ-CX24 and Feedback Questionnaires. Open-ended questions within the Feedback Questionnaires were analyzed to identify themes. RESULTS: Eighty-four patients consented to participate in the study. Of these, 80 (95.2%) completed the EORTC QLQ-CX24 and 76 (90.4%) completed both the EORTC QLQ-CX24 and the Feedback Questionnaires. There were high rates of completion for most items within the EORTC QLQ-CX24 (93-98%), except for items pertaining to vaginal symptoms and sexual health (34-35%). All eligible oncologists participated (n = 9). Overall, patients and oncologists positively endorsed use of the questionnaire during clinical encounters. The majority of patients (80%) and oncologists (89%) reported use of the questionnaire improved communication, including discussion of sensitive topics. Interestingly, only a minority of patients and oncologists stated a perceived preference for electronic completion (18% and 44%, respectively). CONCLUSION: Implementation of the EORTC QLQ-CX24 in gynecologic oncology clinics was feasible and acceptable according to patients and oncologists.
Entities:
Keywords:
Cervix cancer; Patient-reported outcomes; Quality of life; Radiotherapy
Authors: Amanda Caissie; Robert Olson; Lisa Barbera; Jennifer O'Donnell; Carol-Anne Davis; Jennifer Croke; Louise Bird; John Kildea; Erika Brown; Michael Brundage; Michael Milosevic Journal: Curr Oncol Date: 2022-05-19 Impact factor: 3.109
Authors: Eva K Fenwick; Ana M Roldan; Omar A Halawa; Ryan S Meshkin; Nazlee Zebardast; Vesselin Popov; Przemyslaw Lis; David S Friedman; Ecosse L Lamoureux Journal: Transl Vis Sci Technol Date: 2022-02-01 Impact factor: 3.283